
Sign up to save your podcasts
Or


Read our companion blog post with visuals on this episode
This comprehensive analysis examines the impact of GLP-1 receptor agonists on health, particularly their significant efficacy in weight loss and treatment of diabetes. It highlights studies demonstrating the superior performance of newer dual-agonist medications like Zepbound compared to Wegovy, while also outlining the common gastrointestinal side effects and less frequent but more serious adverse events. Beyond metabolic improvements, the sources explore the expanding therapeutic benefits of GLP-1s, including cardiovascular protection, reduction in addiction behaviors, and positive effects on sleep apnea, kidney function, and even neurological health. Finally, the analysis discusses the rapid adoption of these medications in the U.S. amidst a national obesity and diabetes crisis, noting the high financial burden and existing disparities in access.
By Eric Eden3.8
3333 ratings
Read our companion blog post with visuals on this episode
This comprehensive analysis examines the impact of GLP-1 receptor agonists on health, particularly their significant efficacy in weight loss and treatment of diabetes. It highlights studies demonstrating the superior performance of newer dual-agonist medications like Zepbound compared to Wegovy, while also outlining the common gastrointestinal side effects and less frequent but more serious adverse events. Beyond metabolic improvements, the sources explore the expanding therapeutic benefits of GLP-1s, including cardiovascular protection, reduction in addiction behaviors, and positive effects on sleep apnea, kidney function, and even neurological health. Finally, the analysis discusses the rapid adoption of these medications in the U.S. amidst a national obesity and diabetes crisis, noting the high financial burden and existing disparities in access.

337 Listeners

49 Listeners

78 Listeners

1,666 Listeners

395 Listeners

232 Listeners

201 Listeners

334 Listeners

31 Listeners

90 Listeners

70 Listeners

163 Listeners

10 Listeners

20 Listeners